Repligen (RGEN) Tops Q4 EPS by 3c ; Offers Guidance
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $178.19 --0%
EPS Growth %: 0.0%
Financial Fact:
Research and development: 1.89M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: 0.0%
Financial Fact:
Research and development: 1.89M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q4 EPS of $0.44, $0.03 better than the analyst estimate of $0.41. Revenue for the quarter came in at $168 million versus the consensus estimate of $167.67 million.
GUIDANCE:
Repligen sees FY2025 EPS of $1.67-$1.76, versus the consensus of $1.71. Repligen sees FY2025 revenue of $685-710 million, versus the consensus of $692.8 million.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jana Partners urges Cooper Companies to replace CEO and explore asset sales
- Nucor projects Q3 2026 earnings above prior year, below estimates
- Increasing unusual option volume: MIR GFL ACAD XP FRO GRAL DQ
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
